Data from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer

<div>Abstract<p>Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein that is overexpressed on the surface of cancerous prostate cells both in primary tumors and in metastases. Small organic ligands targeting PSMA have been broadly and successfully used to deliver radionuclide payloads to prostate cancer lesions. ¹⁷⁷Lu-PSMA-617 (Pluvicto, a Novartis product) is a PSMA-targeted product that has been recently approved for the treatment of metastatic castration-resistant prostate cancer. By contrast, no small molecule–drug conjugates (SMDC) directed against PSMA have gained marketing authorization yet. In this article, we present the development of novel SMDCs generated by conjugating the tumor-targeting moiety of Pluvicto (here named “OncoPSMA”) to highly cytotoxic auristatin payloads through cleavable linkers, including valine–citrulline, disulfide bridges, and a recently described postprolyl peptidase–cleavable linker [glycine–proline (Gly-Pro)]. The efficiency of payload release at the cancer site and in healthy tissues was assessed via biodistribution studies using mass spectrometry quantification upon systemic administration in tumor-bearing mice. SMDCs based on the Gly-Pro linker mediated the highest payload release in solid tumors compared with widely utilized cathepsin B–cleavable and disulfide linkers. The <i>in vivo</i> efficacy of OncoPSMA-Gly-Pro-monomethyl auristatin E and OncoPSMA-Gly-Pro-monomethyl auristatin F was tested in therapy studies alone and in combination with an antibody–IL2 fusion protein, capable of preferential homing to solid tumors. Combination treatments resulted in complete and durable responses, highlighting the potential benefit of this therapeutic modality to patients with metastatic prostate cancer.</p></div>